Champions Oncology (CSBR) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Champions Oncology (CSBR) has outperformed Kalaris Therapeutics (KLRS) over the past year, losing 25.4% versus a loss of 66.8%. Over five years, CSBR leads with a -51.6% price change compared with -99.5% for KLRS. Champions Oncology is the larger company by market cap ($67.9 million vs $60.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | KLRS |
|---|---|---|
| Share price | $4.88 | $2.56 |
| Market cap | $67.92M | $60.94M |
| 1-day change | -2.59% | -3.76% |
| YTD return | -29.38% | -69.67% |
| 1-year return | -25.38% | -66.84% |
| 5-year return | -51.59% | -99.50% |
| Forward P/E | 48.80 | — |
| EPS (TTM) | $-0.07 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $11.88 |
| 52-week low | $4.59 | $2.51 |
| Distance from 52-week high | -41.28% | -78.45% |
| Average volume | 11.25K | 254.23K |
| Shares outstanding | 13.92M | 23.80M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed KLRS by 41.5 percentage points over the past year.
CSBR vs KLRS FAQ
Which is bigger, Champions Oncology or Kalaris Therapeutics?
Champions Oncology (CSBR) is larger, with a market capitalization of $67.92M compared with $60.94M for Kalaris Therapeutics (KLRS).
Which stock has performed better over the past year, CSBR or KLRS?
CSBR returned -25.38% over the past 12 months, compared with -66.84% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.